Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 2 Clinical Study to Evaluate the Safety and Efficacy of Hemay5394 in Participants With Mild to Moderate Atopic Dermatitis

NCT07877155 is registered in ClinicalTrials.gov with Hemay Pharmaceutical PTY. LTD. as lead sponsor.

NCT NCT07877155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07877155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 2 Clinical Study to Evaluate the Safety and Efficacy of Hemay5394 in Participants With Mild to Moderate Atopic Dermatitis
Lead sponsor
Hemay Pharmaceutical PTY. LTD.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficiency, safety